Food as Medicine, Digital Health, and Medical Devices: The Next Frontier in Healthcare Compliance

By Vivian Egbu

A quiet convergence is underway in healthcare. As federal agencies focus on diet-related chronic disease, medical device, diagnostics, and biotechnology companies are increasingly building products that sit at the intersection of food, nutrition, and clinical care. In July 2026, the U.S. Department of Health and Human Services Office of Inspector General (OIG) issued Advisory Opinion 26-16 (AO 26-16), a favorable opinion addressing a health center’s “food-as-medicine” program that provides free produce boxes and healthy-food vouchers to low-income patients with chronic conditions. Read alongside recent action from HHS, FDA, and the Department of Justice (DOJ), the opinion signals both real opportunity and real compliance risk for companies operating in this space.

For device and biotech companies developing metabolic health, obesity, cardiac, gastrointestinal, and digital nutrition technologies, these developments are increasingly relevant to both product strategy and compliance. Regulators are paying attention to how food and clinical care connect, creating opportunities for well-structured programs while increasing the compliance stakes for companies operating in these converging spaces.

The Government’s Growing Focus on Chronic Disease and Nutrition

Federal health policy has turned sharply toward diet-related chronic disease. In July 2025, HHS, FDA, and the U.S. Department of Agriculture jointly announced an effort to establish a uniform federal definition of “ultra-processed foods” (UPF) expressly linking UPF overconsumption to the nation’s chronic disease epidemic. Agencies have estimated that roughly 70% of packaged products in the U.S. food supply are often considered ultra-processed. This focus creates a policy backdrop in which nutrition, metabolic health, and clinical care are increasingly treated as connected, and in which technologies that measure or influence diet-related outcomes are moving toward the center of the conversation.

HHS OIG’s Favorable “Food-as-Medicine” Opinion

In AO 26-16, OIG evaluated a program in which a federally qualified health center provides eligible low-income patients who have certain chronic conditions, such as diabetes or hypertension, with free produce boxes or healthy-food vouchers, together with nutrition counseling, health assessments, laboratory testing, and related clinical services. OIG concluded that the arrangement implicated both the federal Anti-Kickback Statute (AKS) and the Beneficiary Inducements Civil Monetary Penalty Law (Beneficiary Inducements CMP) because the free food constituted remuneration connected to federally reimbursable services.

No AKS safe harbor applied, and the financial-need-based exception to the Beneficiary Inducements CMP did not apply because the food benefits were tied to other reimbursable services. Even so, OIG exercised its enforcement discretion and declined to impose sanctions, citing the following features of the program:

• Clear clinical objectives. The program was designed to support disease management and improve patient outcomes through access to healthy food, not to drive referrals.
• Targeted eligibility. Participation was limited to patients with specified chronic conditions and demonstrated financial need.
• Limited scope and value. The food benefits were capped in duration and value, reducing the risk of inappropriate inducement.
• Meaningful clinical oversight. Participants received coordinated services, including nutrition counseling and individualized care planning.
• Built-in safeguards. Voucher use was limited to approved healthy-food purchases and paired with monitoring and oversight.

As with all OIG advisory opinions, AO 26-16 binds only the requesting party. Its value lies in the analytical roadmap it offers for structuring nutrition-support programs that regulators are more likely to view as low risk.

FDA’s Increasing Attention to Obesity and Metabolic Health

FDA’s focus on obesity and metabolic health extends to the products being developed to address them. In March 2026, the agency issued final guidance, “Medical Devices with Indications Associated with Weight Loss — Premarket Considerations,” providing the first unified framework for evaluating weight-loss devices, from implantable and endoscopic technologies to digital therapeutics. The guidance arrives as GLP-1 drugs reshape obesity treatment and as device companies pursue gastric stimulation and other metabolic as well as software-based interventions[CZ1] . FDA is also stepping up enforcement in adjacent areas, issuing warning letters to telehealth companies over false or misleading claims about compounded GLP-1 products. For companies developing device-based or digital metabolic health tools, FDA’s expectations for clinical evidence and truthful promotion are rising.

The Rise of Digital Therapeutics and Nutrition Technologies

Much of the innovation in this space is software-driven. Continuous glucose monitors, metabolic trackers, wearables, and AI-powered coaching and nutrition platforms increasingly combine dietary data with clinical decision-making. FDA has signaled growing interest in how these tools are regulated, including through its August 2026 discussion paper and public docket on the regulation of generative AI-enabled medical devices. A central question for many companies is whether a nutrition or wellness tool remains a low-risk “general wellness” product or crosses into medical device territory because of the claims it makes or the clinical decisions it supports.

The Compliance Risks Companies Should Be Watching

Programs and products that link food, nutrition, and clinical care implicate several overlapping bodies of law. Companies should evaluate each of the following before launch:

• Anti-Kickback Statute. Free food, devices, or services provided to patients or providers can be remuneration that induces federally reimbursable orders. Structure matters more than good intentions.
• Beneficiary Inducements CMP. Free patient benefits tied to reimbursable services can trigger liability even where a financial-need exception seems to apply, as AO 26-16 illustrates.
• Advertising and promotional claims. As recent FDA enforcement shows, claims about weight loss, metabolic health, or disease management must be truthful, substantiated, and non-misleading.
• FDA intended-use and device classification. The line between a wellness product and a regulated medical device turns on intended use and claims, and misjudging it carries premarket and enforcement consequences.
• AI-enabled device regulation. Generative and adaptive AI tools raise emerging questions around validation, change control, and postmarket monitoring that FDA is actively working to address.
• DOJ and HHS enforcement priorities. A DOJ–HHS False Claims Act working group is focused on pharmaceutical, device, and provider conduct, including kickbacks and defective or overstated products, increasing exposure for outcome-based claims.

“Food-as-medicine and metabolic health programs are among the most promising areas in healthcare right now, but there is little room for error on compliance. Regulators will look past the mission and ask whether the structure actually limits overutilization, inducement, and misleading claims. Companies that build those safeguards in from the start are the ones that will be able to move quickly.”

Vivian Egbu, Associate Attorney

Practical Takeaways for Medical Device and Biotech Companies

Companies exploring food-as-medicine, metabolic health, or digital nutrition offerings should treat the current environment as one that invites innovation while demanding careful compliance planning. Before launch, evaluate whether a free item or service could increase federally reimbursable utilization, skew clinical decision-making, or inappropriately steer patients, and whether any associated claims outpace the evidence. Tie any nutrition benefit to a legitimate clinical objective, target it to a defined patient population, cap its scope and value, keep provider compensation neutral to volume and value, and use objective, substantiated communications. Confirm the product’s regulatory status early, and document the fraud-and-abuse and promotional analyses so the safeguards are visible, not assumed.

Bottom Line

The intersection of food, digital health, and medical devices is one of the next frontiers in healthcare, and regulators are already there. AO 26-16 shows that a nutrition benefit can implicate the AKS and Beneficiary Inducements CMP yet still present low fraud-and-abuse risk when it is carefully structured. FDA’s obesity, digital health, and AI activity, together with DOJ and HHS enforcement priorities, means clinical benefit and good intentions are not a substitute for a documented compliance analysis. Companies that plan for these regulatory and compliance risks early will be best positioned to lead.

How Gardner Law Can Help

Gardner Law regularly advises medical device, diagnostics, digital health, and biotechnology companies on AKS and Beneficiary Inducements CMP risk assessments, FDA regulatory and promotional strategy, device classification and intended-use questions, AI-enabled software compliance, and the design of patient-facing and nutrition-support programs. We help companies evaluate program structure, claims, reimbursement implications, and compliance guardrails before launch. Please contact us to discuss how these developments may inform a proposed or existing arrangement.